Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol
about
Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumonClinical Pharmacokinetics and Pharmacodynamics of Lenalidomide.Warfarin therapy: in need of improvement after all these years.Pharmacogenetics of anticoagulants.Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays.Selective serotonin re-uptake inhibiting antidepressants and the risk of overanticoagulation during acenocoumarol maintenance treatment.The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors.Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Cytochrome P450 (CYP2C9*2,*3) & vitamin-K epoxide reductase complex (VKORC1 -1639G<A) gene polymorphisms & their effect on acenocoumarol dose in patients with mechanical heart valve replacement.Varenicline: progress in smoking cessation treatment.Interaction between lopinavir/ritonavir and warfarin.Genetic variations and their influence on risk and treatment of venous thrombosis.Quantitative Systems Pharmacology Model to Predict the Effects of Commonly Used Anticoagulants on the Human Coagulation Network.Economic evaluation of rivaroxaban in stroke prevention for patients with atrial fibrillation in Greece.Recent advances in oral anticoagulation for atrial fibrillation.Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure.Renal profiles of anticoagulants.Clinical pharmacokinetics and pharmacodynamics of vildagliptin.New oral anticoagulants: comparative pharmacology with vitamin K antagonists.Pharmacoepidemiological assessment of drug interactions with vitamin K antagonists.Management of antithrombotic therapy in patients undergoing electrophysiological device surgery.Proposed Criteria for the Use of Low-Dose Vitamin K Supplementation in Patients Using Vitamin K Antagonists: A Literature Review of a Clinical Controversy.The effect of fenofibric acid on the pharmacokinetics and pharmacodynamics of warfarin in rats.Effects of adrenolytic mitotane on drug elimination pathways assessed in vitro.Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation.Age-stratified outcome of a genotype-guided dosing algorithm for acenocoumarol and phenprocoumon.Evaluation of a Potential Interaction Between New Regimens to Treat Hepatitis C and Warfarin.P-glycoprotein: a clue to vitamin K antagonist stabilization.Role of ABC transporters in trans-epithelial transport of vitamin K antagonists.A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy.Enantioselective synthesis of coumarins catalyzed by a bifunctional amine-thiourea catalyst.Metal-mediated aminocatalysis provides mild conditions: Enantioselective Michael addition mediated by primary amino catalysts and alkali-metal ions.Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin.Concurrent use of tramadol and oral vitamin K antagonists and the risk of excessive anticoagulation: a register-based nested case-control study.Drug interactions with phenprocoumon and the risk of serious haemorrhage: a nested case-control study in a large population-based German database.Quantitative prediction of the impact of drug interactions and genetic polymorphisms on cytochrome P450 2C9 substrate exposure.Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy.A genome-wide association study of acenocoumarol maintenance dosage.The absence of an interaction between warfarin and cranberry juice: a randomized, double-blind trial.Pharmacological and Non-pharmacological Treatments for Stroke Prevention in Patients with Atrial Fibrillation.
P2860
Q27006860-ADAD99AE-5674-4B14-8438-193A3431ECA3Q33433453-2F7FFABB-6339-466A-80E1-1EB509124960Q33793086-29FBD830-FD89-4526-B65F-924E0EA5D757Q34219746-C7BFC26B-9703-4C05-8EE0-5D3F9323BEECQ35154142-858CFDDF-D5EC-4E87-9F79-1F21A0CAFF6EQ35624607-E813937E-0117-4AC4-8AE0-B136A690D925Q35640455-C098057E-C2A6-44BA-986A-91B098B160ECQ35752584-1CB416D3-B7B4-4D71-89B3-98434F9FEAF6Q36855608-55BA49B2-3505-451B-897E-3397CA3C892FQ36904915-A8FE1E25-4A3B-4CCF-8D6E-B3CF7797F5C8Q36910151-DC878C76-FDBF-4AA7-A160-076DB7A3DABCQ37126654-869F7790-6D20-478F-B350-0A6DE81C5C48Q37367046-DB566543-8141-4595-8D3C-6EA9E2E54F56Q37616932-44865496-74E5-433A-8754-C77A695FD8F3Q37802084-A9C1C36A-D2BD-4BB7-BEA0-644C191C93F8Q37832976-B706F424-FCB5-4BEF-B2E9-F41B61717562Q37879330-DE6A2E9D-8CF4-40CA-942B-31B64C074C49Q37984567-16D80780-9C75-47FC-8276-2B0C44905E3DQ38071973-1F06AC97-F2B1-47D5-A31B-7F0FB4337381Q38253820-86B98B69-1C01-41D3-B317-1B22C1B9E99FQ38364982-AAD9B258-E226-4AFC-A965-BC1ACF9724E3Q38727334-C9205B6B-BFEF-41D3-A3B4-1CC4A4647D09Q38911782-49EF3A37-6049-4629-B798-5FB0E0B81717Q38925278-9E05B74E-AE87-440A-8A9E-C7BF0AFBF7E5Q39023182-3D5E0401-1EE5-4E46-B3D0-964C49D24BD2Q39088514-0562D0C2-5DD9-40AF-BA85-52704C205896Q40597366-D9520C5D-EF4F-4B80-9EFA-9DCB90C210E7Q41535282-440C7A2F-1DE1-48F9-903A-12D306FA594AQ42502722-C3CF4E63-506A-4ABD-8723-94BBD11C8C11Q42627777-8443D72B-22F3-48CE-82BC-7FF9C2A81DF4Q42843933-7A87DEA2-B10A-4BA0-B23A-BDC0584D8969Q43202260-63D54A10-C8C8-4E7E-AE89-D46A8B986257Q43270616-37A5363E-C996-45B4-A56D-42F5F67D82BEQ43970773-E3DFE70E-BC89-4FCE-A263-D118A40CCE01Q44848854-57E6161B-DA30-4DA9-BE46-3051B63C7AC3Q45759815-53AA61D4-6C1D-4A86-81C3-43E9E2069D21Q45880221-6B5FFA09-81A1-4A63-8DAC-8852C72963DEQ45939541-E94B02D5-3764-4940-8B5E-F80856E9D4F6Q45954220-38CD5631-10E3-4D03-BFCF-2F5BC929E91EQ45974877-AC359B53-4AA3-44D4-8759-FC775F2B0092
P2860
Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol
description
2005 nî lūn-bûn
@nan
2005 թուականին հրատարակուած գիտական յօդուած
@hyw
2005 թվականին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Comparative pharmacokinetics o ...... henprocoumon and acenocoumarol
@ast
Comparative pharmacokinetics o ...... henprocoumon and acenocoumarol
@en
Comparative pharmacokinetics o ...... henprocoumon and acenocoumarol
@nl
type
label
Comparative pharmacokinetics o ...... henprocoumon and acenocoumarol
@ast
Comparative pharmacokinetics o ...... henprocoumon and acenocoumarol
@en
Comparative pharmacokinetics o ...... henprocoumon and acenocoumarol
@nl
prefLabel
Comparative pharmacokinetics o ...... henprocoumon and acenocoumarol
@ast
Comparative pharmacokinetics o ...... henprocoumon and acenocoumarol
@en
Comparative pharmacokinetics o ...... henprocoumon and acenocoumarol
@nl
P2860
P921
P3181
P1476
Comparative pharmacokinetics o ...... henprocoumon and acenocoumarol
@en
P2093
P2860
P304
P3181
P356
10.2165/00003088-200544120-00003
P407
P577
2005-01-01T00:00:00Z
P6179
1012884443